Lymphoma clinical trials

The registry lists 5,585 studies for Lymphoma across more than 10 countries. 832 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.

Studies

Recruiting first, then most recently updated. Showing 50 of 5,585 — search for more.

• Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingNCT07524530Phase 21 country
• Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsRecruitingNCT06441331Phase 13 countries
• Impact of Demography, Ethnicity, Co-morbidities and Inequalities on Outcomes in DLBCL Across the UKCHART NetworkNot yet recruitingNCT07813585
• Epco, Zanu, Ritux for R/R FL or MZLRecruitingNCT06563596Phase 21 country
• A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRecruitingNCT04094610Phase 1/211 countries
• Liquid Biopsy Evaluation and Repository Development at Princess MargaretRecruitingNCT037023091 country
• Rutgers University Study of the Genetics of Blood CancersRecruitingNCT077140441 country
• Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 11 country
• Virtual Rehabilitation for Cancer SurvivorsRecruitingNCT05898789Not applicable1 country
• CD30 CAR for Relapsed/Refractory CD30+ T Cell LymphomaRecruitingNCT04083495Phase 21 country
• Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaRecruitingNCT02974647Phase 21 country
• Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)RecruitingNCT04301076Phase 11 country
• Precise Oncology Interventions in Nutrition and Training (OnPoint)RecruitingNCT06534918Not applicable1 country
• A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaRecruitingNCT07015242Phase 23 countries
• Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling by invitationNCT032267041 country
• Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic AnalysisRecruitingNCT014410891 country
• Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasRecruitingNCT03258567Phase 21 country
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingNCT03223610Phase 1/21 country
• Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)RecruitingNCT009235071 country
• CD30 CAR-T in the Treatment of CD30 Positive LymphomaRecruitingNCT07048353Early Phase 11 country
• A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)RecruitingNCT07221500Phase 25 countries
• Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and CancerRecruitingNCT000065181 country
• Collection of Tissue Samples for Cancer ResearchRecruitingNCT009001982 countries
• Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled TrialNot yet recruitingNCT07820033Phase 21 country
• Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory LymphomaRecruitingNCT05798897Phase 11 country
• AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.RecruitingNCT06137144Phase 1/211 countries
• Proton Therapy for Mediastinal Lymphoma (PROMLY)RecruitingNCT07817641Not applicable1 country
• A Study Of Remote Patient Monitoring (RPM) Program For Cancer Patients Initiating Cancer-directed TherapyNot yet recruitingNCT07810400Not applicable1 country
• CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and LymphomaRecruitingNCT04870944Phase 1/22 countries
• Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic MalignanciesNot yet recruitingNCT07710781Not applicable
• Virus-associated Tumour MicroenvironmentRecruitingNCT064712961 country
• Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.RecruitingNCT04915248Phase 21 country
• Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana LinfomiRecruitingNCT05929222Phase 31 country
• Sample Collection and Tracking for the Developmental Therapeutics ClinicRecruitingNCT032695781 country
• A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06624085Phase 12 countries
• Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)RecruitingNCT07509151Phase 35 countries
• RAT-HEMATO : Return to Work After Malignant HemopathyRecruitingNCT06262789Not applicable1 country
• TLN-121 in Relapsed or Refractory Non-Hodgkin LymphomasRecruitingNCT07082803Phase 13 countries
• Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLRecruitingNCT04588922Phase 1/22 countries
• A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruitingNCT06084936Phase 313 countries
• Toxin Exposure and Immune Dysregulation in Non-Hodgkin LymphomaRecruitingNCT076525801 country
• TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaNot yet recruitingNCT07502872Phase 21 country
• A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapyRecruitingNCT04570423Phase 21 country
• Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell TherapyRecruitingNCT052379861 country
• A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory LymphomaNot yet recruitingNCT07791615Phase 2
• Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT07284433Phase 1/22 countries
• Musculoskeletal Ultrasound in Patients With Hematologic MalignanciesNot yet recruitingNCT07785505
• Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell LymphomaRecruitingNCT05826535Phase 1/22 countries
• CD38 Targeted -PET/ CT for Multiple MyelomaRecruitingNCT07782944Not applicable1 country
• A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin LymphomaRecruitingNCT07192471Phase 13 countries